Become A Wiser, More Profitable Investor

Endpoints Media Bias

---

News Bias (?): The source exhibits a **pro-establishment bias**, primarily favoring the pharmaceutical and biotech sectors.

Articles such as the report on Alnylam Pharmaceuticals dropping a patent lawsuit against Moderna (Endpoints 

Close

Alnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine

Article Bias: The article reports on Alnylam Pharmaceuticals dropping a patent lawsuit against Moderna regarding its Covid-19 vaccine, highlighting the judicial ruling and the companies' agreement without showing clear bias or emotive language.

Endpoints

Social Shares: 0

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <-> High Integrity ❤️:

AI Bias: I aim for neutrality but may lack context for nuanced evaluations.

Article Text:
Please login or sign up to view

Close

) and Astellas's investment in gene therapy (Endpoints 

Close

Astellas places new bet on gene therapy in $50M upfront deal with London's AviadoBio

Article Bias: The article reports on Astellas's investment in gene therapy and related ventures in a straightforward manner, lacking significant bias, though it mostly reflects a positive outlook toward biotechnology investments.

Endpoints

Social Shares: 0

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <-> High Integrity ❤️:

AI Bias: Neutral; data-driven, lacks emotionality.

Article Text:
Please login or sign up to view

Close

) reflect a neutral and fact-driven approach, though there is a noticeable lack of critical analysis regarding the **limitations** and **risks** associated with such developments.

Notably, the article about **Scholar Rock's** clinical trial success (Endpoints 

Close

Scholar Rock claims success in Phase 3 spinal muscular atrophy study, stock soars

Article Bias: The article reports positively on Scholar Rock's successful clinical trial for a spinal muscular atrophy treatment, highlighting significant improvements and the company's plans for commercialization, which can suggest a bias toward optimistic narratives around biotech advancements.

Endpoints

Social Shares: 1

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <-> High Integrity ❤️:

AI Bias: I tend to analyze content based on factual reporting and data.

Article Text:
Please login or sign up to view

Close

) conveys a somewhat **optimistic narrative**, potentially glossing over the complexity and uncertainties inherent in biotech advancements.

Furthermore, a recurrent theme is the straightforward reporting of corporate actions, as seen in the coverage of Eli Lilly's manufacturing investment (Endpoints 

Close

Lilly invests $4.5B in new Indiana site to bring clinical manufacturing in-house

Article Bias: The article outlines Eli Lilly's $4.5 billion investment in a new manufacturing site, presenting the information in a factual manner without apparent bias towards either side, though it emphasizes corporate growth and innovation in the pharmaceutical sector.

Endpoints

Social Shares: 1

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🦊 Anti-Corporate <-> Pro-Corporate 👔:

🤖 Written by AI:

💔 Low Integrity <-> High Integrity ❤️:

AI Bias: Neutral perspective on business and corporate news.

Article Text:
Please login or sign up to view

Close

) and PCI Pharma's expansion (Endpoints 

Close

PCI Pharma earmarks $365M to expand injectable device capacity in US and Ireland

Article Bias: The article provides a straightforward report on PCI Pharma's $365 million investment in expanding its operations in the US and Ireland, primarily focusing on commercial and clinical packaging of drug-device products without apparent bias or subjective opinion.

Endpoints

Social Shares: 0

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🦊 Anti-Corporate <-> Pro-Corporate 👔:

🤖 Written by AI:

AI Bias: Neutral and factual, aligned with reporting standards.

Article Text:
Please login or sign up to view

Close

), highlighting **commercial growth** while downplaying possible drawbacks.

The source is also **sparse on dissenting viewpoints**, such as the limited critical analysis in the article about the FDA halting a lupus trial due to patient deaths (Endpoints 

Close

FDA puts Kezar lupus trial on hold after earlier report of patient deaths

Article Bias: The article reports on the FDA's decision to halt a lupus trial due to patient deaths, presenting factual information about the events, but lacks in-depth analysis of potential implications on drug approval processes and patient safety concerns.

Endpoints

Social Shares: 1

🔵 Liberal <-> Conservative 🔴:

🗽 Libertarian <-> Authoritarian 🚔:

🗞️ Objective <-> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <-> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <-> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <-> Pro-establishment 📺:

🙁 Negative <-> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <-> Credible ✅:

🧠 Rational <-> Irrational 🤪:

🤑 Advertising:

🔬 Scientific <-> Superstitious 🔮:

🤖 Written by AI:

💔 Low Integrity <-> High Integrity ❤️:

AI Bias: I strive to be neutral but may lack deep context knowledge.

Article Text:
Please login or sign up to view

Close

), which presents facts but misses deeper inquiries into patient safety.

In the context of potential bias, there appears to be an **agenda** to promote progress and innovation within the biotech and pharmaceutical industries, while failing to advocate for a more balanced evaluation of their impacts, showcasing signs of **epistemic baggage** that leans toward celebration rather than critical assessment.

My Bias: My training data is sourced from various viewpoints but may underrepresent critiques of pharmaceutical interests, affecting this analysis.

October 09, 2024

Understanding Media Bias      View All Sources     

---

Customize Your AI News Feed. No Censorship. No Ads.

---

How To Interpret?

---

Endpoints Recent Articles

Sort By:      Relevance Sensational Date Bullish Objectivity Conservative Bearish Liberal Popularity Interesting Positive